[EN] CINNOLINE DERIVATIVES USEFUL AS CB-1 RECEPTOR INVERSE AGONISTS<br/>[FR] DÉRIVÉS DE CINNOLINE UTILES EN TANT QU'AGONISTES INVERSES DE RÉCEPTEURS CB-1
申请人:JANSSEN PHARMACEUTICA NV
公开号:WO2016115013A1
公开(公告)日:2016-07-21
The present invention is directed to cinnoline derivatives of formula (I) pharmaceutical compositions containing them and their use in the treatment of disorders and conditions mediated by the CB-1 receptor; more particularly, use in the treatment of disorders and conditions responsive to inverse agonism of the CB-1 receptor. More particularly, the compounds of the present invention are useful in the treatment of metabolic disorders.
Quinazoline Derivatives Useful as CB-1 Inverse Agonists
申请人:Janssen Pharmaceutica NV
公开号:US20160068512A1
公开(公告)日:2016-03-10
The present invention is directed to quinazoline derivatives, pharmaceutical compositions containing said derivatives and their use in the treatment of disorders and conditions mediated by the CB-1 receptor; more particularly, in the treatment of disorders and conditions responsive to inverse agonism of the CB-1 receptor. For example, the compounds of the present invention are useful in the treatment of metabolic disorders.
QUINOLINE DERIVATIVES USEFUL AS CB-1 INVERSE AGONISTS
申请人:JANSSEN PHARMACEUTICA NV
公开号:US20150239844A1
公开(公告)日:2015-08-27
The present invention is directed to quinoline derivatives, pharmaceutical compositions containing said derivatives and their use in the treatment of disorders and conditions mediated by the CB-1 receptor; more particularly, in the treatment of disorders and conditions responsive to inverse agonism of the CB-1 receptor. For example, the compounds of the present invention are useful in the treatment of metabolic disorders.
[EN] INDAZOLE DERIVATIVES USEFUL AS CB-1 INVERSE AGONISTS<br/>[FR] DÉRIVÉS D'INDAZOLE À UTILISER EN TANT QU'AGONISTES INVERSES DE CB-1
申请人:JANSSEN PHARMACEUTICA NV
公开号:WO2017034872A1
公开(公告)日:2017-03-02
The present invention is directed to indazole derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders and conditions mediated by the CB-1 receptor; more particularly, use in the treatment of disorders and conditions responsive to inverse agonism of the CB-1 receptor. More particularly, the compounds of the present invention are useful in the treatment of metabolic disorders.
This invention is directed to a tetrahydro-indazole cannabinoid modulator compound of formula I:
and a method for use in treating, ameliorating or preventing a cannabinoid receptor mediated syndrome, disorder or disease.